Related Experiment Video
Updated: May 5, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Influence of azathioprine on hepatic reserve in chronic active liver disease
Abstract:
The kinetics of hepatic indocyanine green (ICG) uptake have been analysed in 14 patients with chronic active liver disease. The removal of incremental, submaximal ICG doses were compatible with Michaelis-Menten kinetics in approximately 80% of studies in patients allowing the calculation of the maximal rate of removal (Rmax) and the Michaelis constant (Km). Neither of these variables correlated with other laboratory indices of liver function. Although determinations of Rmax before and after a two-weeks trial of azathioprine therapy were not significantly different, in two patients Rmax was markedly reduced by treatment. It is concluded that azathioprine over the short term does not improve the liver's reserve for ICG removal; in fact, in isolated cases this drug may be detrimental.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

